Multiple System Atrophy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's "Multiple System Atrophy Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Multiple System Atrophy Pipeline? Click here to explore the therapies and trials making headlines @ Multiple System Atrophy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Multiple System Atrophy Pipeline Report

* On 20 October 2025, Biogen initiated a study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.
* On 16 October 2025, Novartis Pharmaceuticals announced a Phase IIIb open-label, single arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101B in participants with SMA aged 2 to
* On 15 October 2025, H. Lundbeck A/S conducted a study will consist of a 3-6-week screening period, a 72-week placebo-controlled period (PCP), and will include a 72-week optional dose-blinded open-label treatment extension (OLE) period. Participants in the PCP will be randomized to Lu AF82422 high dose, Lu AF82422 low dose or placebo (1:1:1). All participants entering the OLE will receive Lu AF82422 during the OLE. Participants will receive intravenous infusions approximately every 4 weeks during both the PCP and OLE.
* On 14 October 2025, Teva Branded Pharmaceuticals announced a study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286.
* DelveInsight's Multiple System Atrophy Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Multiple System Atrophy treatment.
* The leading Multiple System Atrophy Companies such as Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S and others.
* Promising Multiple System Atrophy Therapies such as TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241 , and others.

Want to know which companies are leading innovation in Multiple System Atrophy? Dive into the full pipeline insights @ Multiple System Atrophy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Multiple System Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Multiple System Atrophy Pipeline Report also highlights the unmet needs with respect to the Multiple System Atrophy.

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.

Multiple System Atrophy Emerging Drugs Profile

* Lu AF82422: H. Lundbeck A/S

Lu AF82422 is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular -syn and thereby is believed to prevent uptake and inhibit seeding of aggregation. Lu AF82422 has an active Fc region, which may increase immune-mediated clearance of -syn/mAb complexes through microglia mediated uptake. Lu AF82422 is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S. The drug is currently investigated in Phase III clinical trial for MSA patients.

* ATH434: Alterity Therapeutics

ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce -synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase I studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase II clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase II Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the US FDA and the European Commission.

* AB-1005: AskBio

AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, which allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with magnetic resonance imaging (MRI)-monitored convection enhanced delivery. GDNF is a homodimer that is a distantly related member of the transforming growth factor- superfamily. In midbrain neuronal cell cultures, recombinant human GDNF promoted the survival and morphological differentiation of dopaminergic neurons and increased their high-affinity dopamine uptake.

If you're tracking ongoing Multiple System Atrophy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Multiple System Atrophy Treatment Drugs [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Multiple System Atrophy Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
* Multiple System Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

Multiple System Atrophy Companies

Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others.

Multiple System Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Multiple System Atrophy Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Multiple System Atrophy Pipeline Report covers it all - check it out now @ Multiple System Atrophy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Multiple System Atrophy Pipeline Report

* Coverage- Global
* Multiple System Atrophy Companies- Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S and others.
* Multiple System Atrophy Therapies- TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241 , and others.
* Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Multiple System Atrophy Treatment landscape in this detailed analysis @ Multiple System Atrophy Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Multiple System Atrophy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Multiple System Atrophy- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* NASP: Swedish Orphan Biovitrum A
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PRX-115: Protalix Biotherapeutics Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Multiple System Atrophy Key Companies
* Multiple System Atrophy Key Products
* Multiple System Atrophy- Unmet Needs
* Multiple System Atrophy- Market Drivers and Barriers
* Multiple System Atrophy- Future Perspectives and Conclusion
* Multiple System Atrophy Analyst Views
* Multiple System Atrophy Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-system-atrophy-pipeline-drugs-insights-report-2025-clinical-trials-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.